Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
VP3.15 dihydrobromide
Cat. No.:
0225LY-1040
Appearance:
Solid
Purity:
≥96%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
VP3.15 dihydrobromide is an orally bioavailable dual inhibitor of PDE7 and GSK3, capable of penetrating the central nervous system.
Synonym:
1281681-33-1; VP3.15 (dihydrobromide); N-(2-morpholin-4-ylethyl)-2,3-diphenyl-1,2,4-thiadiazol-5-imine;dihydrobromide; VP-3.15 dihydrobromide; VP3.15 2HBr; VP-3.15 2HBr; (Z)-N-(2,3-diphenyl-1,2,4-thiadiazol-5(2H)-ylidene)-2-morpholinoethanamine dihydrobromide; (Z)-N-(2-Morpholinoethyl)-2,3-diphenyl-1,2,4-thiadiazol-5(2H)-imine dihydrobromide; (Z)-N-(2-Morpholinoethyl)-2,3-diphenyl-1,2,4-thiadiazol-5(2H)-iminedihydrobromide; N-(2,3-diphenyl-1,2,4-thiadiazol-5-ylidene)-2-(morpholin-4-yl)ethanamine dihydrobromide
CAS No.:
1281681-33-1
Compound CID:
57326492
Formula:
C20H24Br2N4OS
Formula Weight:
528.3
Specification
Targets&IC50:
PDE7: 1.59 μM; GSK-3: 0.88 μM
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
VP3.15 dihydrobromide can be used in neurodegeneration research to explore the dual inhibition of GSK-3 and PDE5.
Library Information
Target:
PDE; GSK-3
Receptor:
GSK-3; PDE7
Pathways:
Stem cell regulation; PI3K/Akt/mTOR signaling; Metabolism
Plate Number:
AOCL-14
Plate Location:
d3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
22.5 mg/mL; 42.59 mM
